Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by G1945Von Mar 11, 2016 8:39am

176 Views

Post# 24647128

T-RVX ... Then & Now

A bit of SP history :

-The share price (SP) pretty much hovered at 70 cents in 2014
-Declined to 50 cents towards year end 2014 tax selling
-Natural incline of SP post tax selling season.... 2015
-Reached $1.05 March 8, 2015 Roth Capital Conference
-Reached $1.80 April 7, 2015 due to 2 patents in China
-Reached $2.87 April 27, 2015 Hepa Deal
-Steady decline since
-Now SP stands at $1.42... March 2016

-Roth Capital Conference March 13-16, 2016

G1945V

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity